StockNews.com initiated coverage on shares of BioLineRx (NASDAQ:BLRX – Free Report) in a research report report published on Saturday. The brokerage issued a hold rating on the biotechnology company’s stock.
Separately, HC Wainwright dropped their price target on BioLineRx from $21.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, November 25th.
Read Our Latest Stock Report on BioLineRx
BioLineRx Price Performance
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of BLRX. PVG Asset Management Corp bought a new stake in shares of BioLineRx in the 2nd quarter worth about $70,000. Atria Investments Inc raised its position in BioLineRx by 27.9% in the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 29,193 shares during the period. Finally, CVI Holdings LLC bought a new stake in BioLineRx in the second quarter worth about $462,000. 1.56% of the stock is owned by hedge funds and other institutional investors.
About BioLineRx
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Featured Articles
- Five stocks we like better than BioLineRx
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- What Are Earnings Reports?
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- Top Stocks Investing in 5G Technology
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.